French drug producer Sanofi-Aventis SA expressed that on Wednesday its investigational blood vessel medicine NV1FGF botched to convene its objective in a tardy - phase clinical assessment.

The news drive shares of U. S. biotechnology corporation Vical Inc that authorize the drug to Sanofi, to a 52-week low on Wednesday.

The action botched in a Stage III learnt to display pre-eminence contrasted with a placebo in preclude most important confiscation or fatality for patients of vital limb ischemia, which is distinguished by the impediment of blood vessel that reduces blood gush to hands, legs and feet.

Extensive outcome of the ordeal will be unfilled on Nov. 16 in Chicago at the American Heart Association Congress.

Sanofi expressed that it is at the moment appraising all alternatives on expansion of the conduct. An analyst adds that the NV1FGF information was unenthusiastic for Sanofi, although insignificant.

On Wednesday, Jean Jacques Le Fur, analyst with Oddo Securities, in an investigation note inscribed that still if it's unacceptable; it's not an overall shock since they know this project was perilous. He had anticipated the drug's sales aptitude at EUR355 million a year. Oddo grades Sanofi a buy with a EUR60-a-share object price. The information was taken up much more pessimistically for Vical, which was downward by 35% to $2.49 in current trading, subsequent to prior drumming a 52-week low of $2.25.